FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200294788> ?p ?o ?g. }

• W4200294788 abstract "Background Despite recent advances, there is an urgent need for agents targeting HER2-expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a dendritic cell (DC) vaccine targeting HER2 in patients with metastatic cancer or bladder cancer at high risk of relapse. Patients and Methods Part 1 of the study enrolled patients with HER2-expressing metastatic cancer that had progressed after at least standard treatment and patients who underwent definitive treatment for invasive bladder cancer with no evidence of disease at the time of enrollment. Part 2 enrolled patients with HER2-expressing metastatic cancer who had progressed after anti-HER2 therapy. The DC vaccines were prepared from autologous monocytes and transduced with an adenoviral vector expressing the extracellular and transmembrane domains of HER2 (AdHER2). A total of five doses were planned, and adverse events were recorded in patients who received at least one dose. Objective response was evaluated by unidimensional immune-related response criteria every 8 weeks in patients who received at least two doses. Humoral and cellular immunogenicity were assessed in patients who received more than three doses. Results A total of 33 patients were enrolled at four dose levels (5 × 10 6 , 10 × 10 6 , 20 × 10 6 , and 40 × 10 6 DCs). Median follow-up duration was 36 weeks (4–124); 10 patients completed five doses. The main reason for going off-study was disease progression. The main adverse events attributable to the vaccine were injection-site reactions. No cardiac toxicity was noted. Seven of 21 evaluable patients (33.3%) demonstrated clinical benefit (1 complete response, 1 partial response, and 5 stable disease). After ≥3 doses, an antibody response was detected in 3 of 13 patients (23.1%), including patients with complete and partial responses. Lymphocytes from 10 of 11 patients (90.9%) showed induction of anti-HER2 responses measured by the production of at least one of interferon-gamma, granzyme B, or tumor necrosis factor-alpha, and there were multifunctional responses in 8 of 11 patients (72.7%). Conclusions The AdHER2 DC vaccine showed evidence of immunogenicity and preliminary clinical benefit in patients with HER2-expressing cancers, along with an excellent safety profile. It shows promise for further clinical applications, especially in combination regimens." @default.
• W4200294788 created "2021-12-31" @default.
• W4200294788 creator A5002383402 @default.
• W4200294788 creator A5006730842 @default.
• W4200294788 creator A5013891213 @default.
• W4200294788 creator A5018687194 @default.
• W4200294788 creator A5021930028 @default.
• W4200294788 creator A5024934444 @default.
• W4200294788 creator A5025441472 @default.
• W4200294788 creator A5026833249 @default.
• W4200294788 creator A5035283039 @default.
• W4200294788 creator A5037223246 @default.
• W4200294788 creator A5044239219 @default.
• W4200294788 creator A5045107557 @default.
• W4200294788 creator A5051241427 @default.
• W4200294788 creator A5056265030 @default.
• W4200294788 creator A5062001972 @default.
• W4200294788 creator A5072166479 @default.
• W4200294788 creator A5072223571 @default.
• W4200294788 creator A5075618779 @default.
• W4200294788 creator A5077818396 @default.
• W4200294788 creator A5081585105 @default.
• W4200294788 creator A5090769479 @default.
• W4200294788 date "2021-12-16" @default.
• W4200294788 modified "2023-10-12" @default.
• W4200294788 title "Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy" @default.
• W4200294788 cites W129996036 @default.
• W4200294788 cites W1566445646 @default.
• W4200294788 cites W1576367608 @default.
• W4200294788 cites W1593325979 @default.
• W4200294788 cites W1967010387 @default.
• W4200294788 cites W1973101373 @default.
• W4200294788 cites W1977823971 @default.
• W4200294788 cites W1995242599 @default.
• W4200294788 cites W2000028774 @default.
• W4200294788 cites W2007510256 @default.
• W4200294788 cites W2013429820 @default.
• W4200294788 cites W2017935881 @default.
• W4200294788 cites W2020372547 @default.
• W4200294788 cites W2027542837 @default.
• W4200294788 cites W2030612376 @default.
• W4200294788 cites W2032231392 @default.
• W4200294788 cites W2056579307 @default.
• W4200294788 cites W2068326740 @default.
• W4200294788 cites W2069410547 @default.
• W4200294788 cites W2078112275 @default.
• W4200294788 cites W2081082908 @default.
• W4200294788 cites W2089187782 @default.
• W4200294788 cites W2094945699 @default.
• W4200294788 cites W2098983774 @default.
• W4200294788 cites W2100158834 @default.
• W4200294788 cites W2100439220 @default.
• W4200294788 cites W2101076675 @default.
• W4200294788 cites W2103959341 @default.
• W4200294788 cites W2115759102 @default.
• W4200294788 cites W2117241186 @default.
• W4200294788 cites W2124863263 @default.
• W4200294788 cites W2133105825 @default.
• W4200294788 cites W2140882524 @default.
• W4200294788 cites W2141393790 @default.
• W4200294788 cites W2154834163 @default.
• W4200294788 cites W2165537599 @default.
• W4200294788 cites W2167860325 @default.
• W4200294788 cites W2289073238 @default.
• W4200294788 cites W2507354993 @default.
• W4200294788 cites W2560367415 @default.
• W4200294788 cites W2584922809 @default.
• W4200294788 cites W2611130520 @default.
• W4200294788 cites W2769940530 @default.
• W4200294788 cites W2783112448 @default.
• W4200294788 cites W2794839527 @default.
• W4200294788 cites W2795884909 @default.
• W4200294788 cites W2800084163 @default.
• W4200294788 cites W2800143855 @default.
• W4200294788 cites W2886161066 @default.
• W4200294788 cites W2887577080 @default.
• W4200294788 cites W2888063816 @default.
• W4200294788 cites W2912980938 @default.
• W4200294788 cites W2915300970 @default.
• W4200294788 cites W2943699531 @default.
• W4200294788 cites W2983357423 @default.
• W4200294788 cites W2984410235 @default.
• W4200294788 cites W2999754525 @default.
• W4200294788 cites W3018222852 @default.
• W4200294788 cites W3119005666 @default.
• W4200294788 cites W3147820834 @default.
• W4200294788 cites W36309855 @default.
• W4200294788 cites W4239989216 @default.
• W4200294788 doi "https://doi.org/10.3389/fonc.2021.789078" @default.
• W4200294788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34976830" @default.
• W4200294788 hasPublicationYear "2021" @default.
• W4200294788 type Work @default.
• W4200294788 citedByCount "4" @default.
• W4200294788 countsByYear W42002947882022 @default.
• W4200294788 countsByYear W42002947882023 @default.
• W4200294788 crossrefType "journal-article" @default.
• W4200294788 hasAuthorship W4200294788A5002383402 @default.
• W4200294788 hasAuthorship W4200294788A5006730842 @default.
• W4200294788 hasAuthorship W4200294788A5013891213 @default.
• W4200294788 hasAuthorship W4200294788A5018687194 @default.

• next